Verrica Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Verrica Pharmaceuticals Inc. has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2018 Equity Incentive Plan.
NASDAQ
Verrica Pharmaceuticals files a revised proxy statement to correct errors and include additional data tagging, while also seeking stockholder approval for a reverse stock split.
NASDAQ
DEFA14A: Verrica Pharmaceuticals Inc. Sets Date for 2025 Annual Meeting, Proposes Reverse Stock Split
Verrica Pharmaceuticals Inc. will hold its annual meeting on June 5, 2025, and is seeking stockholder votes on director elections, executive compensation, auditor ratification, and a potential reverse stock split.
NASDAQ
DEF: Verrica Pharmaceuticals Announces Annual Meeting of Stockholders and Proposes Reverse Stock Split
Verrica Pharmaceuticals will hold its annual meeting on June 5, 2025, to vote on director elections, executive compensation, auditor ratification, and a potential reverse stock split.
NASDAQ
Verrica Pharmaceuticals Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 6, 2024, outlining key proposals for shareholder voting.
NASDAQ
Verrica Pharmaceuticals has announced its annual meeting of stockholders to be held on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.